Here are some pictures of the first edition
To adress the unmet need to dispose of relevant tools to value the efficacy of treatments for red blood cell disorders, INNOVHEM has developed two important and unique innovations :a simple and accurate method to quantify fetal hemoglobin in each red blood cell and a specific new method to measure intravascular hemolysis. Together with several generic biological assays, INNOVHEM offers a comprehensive and innovative platform that supports the development of new treatments for red blod cell pathologies, from preclinical to phase IV evaluation.
SYNSIGHT Pharmaceuticals aims to make Drug Discovery faster, cheaper and smarter. Early-Stage Drug Discovery includes many Design-and-Test cycles. A large Pharma company may go through 25 cycles or more in a single year! This is where Synsight comes in: we help our clients and partners to make focused decisions on which molecules to make; how and why certain molecules exert a biological activity (or fail to); how to enhance the activity or selectivity of lead molecules, or make them more drug-like; and even how to find new indications for known drugs.